Hisun Pharmaceutical: Subsidiary's new drug HSK46575 tablets receive acceptance of IND application for new indications.

Hisilicon announced that its subsidiary, Liaoning Hisilicon Pharmaceutical, recently received a "Notice of Acceptance" from the National Medical Products Administration. The clinical trial application for its independently developed innovative drug HSK46575 tablets with the indication "used in combination with Olaparib tablets or in combination with Docetaxel and Prednisone tablets for the treatment of prostate cancer" has been accepted. This drug is classified as a Class 1 chemical drug and received approval for clinical trials for the indication of "prostate cancer" in December 2024. It is currently undergoing Phase I clinical studies. However, the research and development of innovative drugs come with high risks, and the company will disclose further developments.